A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)

NCT03975114 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

460

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Chemotherapy
DRUG: Durvalumab
DRUG: Tremelimumab

Sponsor

National Cancer Institute, Naples

Collaborators

[object Object]
[object Object]